Fralin Biomedical Research Institute at Virginia Tech Carillion, Roanoke, VA, 24016, USA.
Center for Vascular and Heart Research, Virginia Tech, Roanoke, VA, 24016, USA.
Nanotheranostics. 2021 Jul 5;5(4):488-498. doi: 10.7150/ntno.62213. eCollection 2021.
Extracellular Vesicles (EVs) are cell-secreted nanovesicles that have unique potential for encapsulating and targeting "difficult-to-drug" therapeutic cargos. Milk provides an enriched source of EVs, and of particular interest to the drug delivery field, small EVs. Small EVs are distinguished from large EVs by membrane components, biogenesis mechanism and downstream functionality - in particular, small EVs are primarily composed of exosomes, which show high stability and naturally function in the targeted delivery of biological materials to cells. Moreover, bovine milk is abundantly produced by the dairy industry, widely consumed, and generally well tolerated by humans. Importantly, there is evidence that milk exosomes and small EVs are efficiently taken up into the circulation from the gut, providing the opportunity for their use in administration of therapeutics such as microRNAs or peptides not typically available via an oral route. Unfortunately, present methods for isolation do not efficiently separate EVs from milk proteins, resulting in contamination that is not desirable in a clinical-grade therapeutic. Herein, we present novel EV purification methods focused on optimized timing and levels of temperature and divalent cation chelation. Incorporation of these solubilization steps into centrifugation- and tangential flow filtration-based methods provide large amounts of purified small EVs at ultra-dense concentrations, which are substantially free from contaminating milk proteins. Remarkably, these ultra-dense isolates equal 10 to 15% of the starting volume of milk indicating a prodigious rate of small EV production by mammary glands. Our approach enables gentle, scalable production of ultrastructurally and functionally intact small EVs from milk, providing a path to their industrial scale purification for oral delivery of therapeutic biologics and small drugs.
细胞外囊泡(EVs)是细胞分泌的纳米囊泡,具有封装和靶向“难药”治疗性 cargo 的独特潜力。牛奶是 EVs 的丰富来源,特别是对药物输送领域而言,是小 EVs。小 EVs 与大 EVs 区别在于膜成分、生物发生机制和下游功能——特别是小 EVs 主要由外泌体组成,外泌体具有高稳定性,并且天然作用是将生物材料靶向递送至细胞。此外,牛奶由乳制品行业大量生产,被广泛消费,且通常被人类很好地耐受。重要的是,有证据表明,牛奶外泌体和小 EVs 从肠道中被有效地吸收到循环中,为其在治疗剂如 microRNAs 或肽的给药中提供了机会,这些治疗剂通常不能通过口服途径获得。遗憾的是,目前的分离方法不能有效地将 EVs 与牛奶蛋白分离,导致在临床级治疗中不希望存在的污染。在此,我们提出了新的 EV 纯化方法,重点是优化温度和二价阳离子螯合的时间和水平。将这些溶解步骤纳入基于离心和切向流过滤的方法中,可在超浓缩浓度下提供大量纯化的小 EVs,这些小 EVs实质上不含污染的牛奶蛋白。值得注意的是,这些超浓缩物相当于起始牛奶体积的 10%至 15%,表明乳腺产生小 EVs 的速度非常快。我们的方法能够从牛奶中温和、规模化地生产出超结构和功能完整的小 EVs,为其工业规模纯化提供了一条途径,可用于口服递送治疗性生物制剂和小分子药物。